Immuno-oncologic approach is the 3rd generation anti-cancer treatment that uses a novel mechanism of destroying cancer cells through the activation of patient’s immune system. It does not produce side effects of chemotherapy or resistance from the usage of targeted anti-cancer therapy. It is hope to be efficacious for both of hematological and solid tumors.

Immuno-oncologic agents utilize the patient's internal immune system, brings complete cure with little to no side effects. However, it is known to have definite effects only to 25% of the patient population. FDA has approved four immno-oncology drugs, Keytruda, Opdivo, Tecentriq, Yervoy.

Kainos Medicine is developing novel small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. Through our core competency of medicinal chemistry technology, we are developing candidates.